CRCHD Announces New CURE Distinguished Scholars Seminar Series
June 21, 2017, by CRCHD Staff
In celebration of 21 years of the Continuing Umbrella of Research Experiences (CURE) program, the Center to Reduce Cancer Health Disparities (CRCHD) is pleased to announce a new scientific seminars series, the CURE Distinguished Scholars Seminar Series.
This semiannual, scientific seminar series aims to recognize former CURE scholars for having made seminal contributions to the fields of cancer and cancer health disparities research and for being a role models for other scientists from backgrounds that are underrepresented in cancer research.
The inaugural guest seminar speaker is Lewis R. Roberts, M.B., Ch.B., Ph.D., Peter and Frances Georgeson Professor in Gastroenterology Cancer Research at the Mayo Clinic in Rochester, MN.
Dr. Roberts will present "Teams: Leveraging the Power of Collaboration to Advance Your Science and Reduce Disparities." He will discuss his work in liver and bile duct cancers, featuring his research on the mechanisms of liver and biliary carcinogenesis and biomarkers to improve diagnosis as well as the diagnosis and treatment of hepatitis and liver cancer in immigrant African and U.S. communities.
This inaugural seminar will take place on Wednesday, June 28th from 1:00 to 2:30 PM at the NCI Shady Grove Campus in 2W910/912. If you are unable to attend in person, please register to join via WebEx at http://bit.ly/2rtCjm9.
The next CURE Distinguished Scholars Seminar is scheduled for October 2017, and will be delivered by former CURE scholar, John Carethers, M.D., MACP, who will present his work in hereditary colon cancer, tumor progression, and colorectal cancer disparities. Dr. Carethers is John G. Searle Professor and Chair, Department of Internal Medicine and Professor of Human Genetics at the University of Michigan.
In May 2018, CRCHD is pleased to host former CURE scholar, Levi Garraway, M.D., Ph.D., who will present his research on the molecular and genomic characterization of human solid tumors. Dr. Garraway is Senior Vice President of Global Oncology at the Eli Lilly and Company.
The CURE program supports underrepresented individuals across the academic continuum — beginning in middle school and continuing to cancer research independence — through a pipeline of research funding opportunities.